Protocol Title: EA9161 - A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Target Population: Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) that is CCND1/IGHG1 Fusion Negative and (11;14) Negative

Summary: This phase III trial studies how well Ibrutinib and Obinutuzumab with or without Venetoclax work in treating patients with Chronic Lymphocytic Leukemia.

Key Eligibility Criteria:
- Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Includes documentation of:
  - Biopsy-proven SLL OR diagnosis of CLL as evidenced by all of the following:
    - Peripheral blood lymphocyte count > 5 x10⁹/L
    - Immunophenotype consistent with CLL
  - Negative FISH analysis for t(11;14)(lgH/CCND1) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 staining on involved tissue biopsy
- No prior chemotherapy, BTK inhibitor therapy, Venetoclax, small molecule signaling inhibitor, or monoclonal anti-body therapy for treatment of CLL or SLL
- Has met at least one of the following indications for treatment:
  - Evidence of progressive marrow failure as manifested by the development of worsening anemia (hemoglobin [Hg] < 11 g/dl) and/or thrombocytopenia (platelets < 100 x 10⁹/L)
  - Symptomatic or progressive lymphadenopathy, splenomegaly, or hepatomegaly
  - One or more of the following disease-related symptoms:
    - Weight loss ≥ 10% within the previous 6 Months
    - Grade 2 or 3 fatigue attributed to CLL
    - Fevers > 100.5° F for 2 Weeks without evidence of infection
    - Clinically significant night sweats without evidence of infection
  - Progressive lymphocytosis (not due to the effects of corticosteroids) with an increase of > 50% over a two-month period or an anticipated doubling time of less than six Months
- Must be between 18 to 69 years of age
- ECOG Performance Status 0-2
- Age ≥ 18 years and < 70
- No deletion of 17p13 on cytogenetic analysis by FISH
- No other active primary malignancy (other than non-melanomatous skin cancer or carcinoma in situ of the cervix) requiring treatment or limiting expected survival to ≤ 2 Years
- Must undergo assessment with Timed Up and Go (TUG) Test
- Must be able to receive Xanthine Oxidase Inhibitor or Rasburicase for Tumor Lysis Syndrome (TLS) prophylaxis

Contacts:
Principal Investigator: Carter Davis, MD
Research Nurses (RN): Elise Curry (elisemarie.curry@ochsner.org, ext.28084)
Elsa Levenes (elsa.levenes@ochsner.org, ext. 21094)

For additional information: https://clinicaltrials.gov/ct2/show/study/NCT03701282